Northeast Investment Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.36M Sell
27,819
-1,073
-4% -$161K 0.16% 70
2026
Q1
$4.41M Sell
28,892
-2,006
-6% -$307K 0.18% 66
2025
Q4
$4.26M Sell
30,898
-72
-0.2% -$9.43K 0.17% 66
2025
Q3
$3.97M Hold
30,970
0.16% 67
2025
Q2
$3.75M Sell
30,970
-66
-0.2% -$7.44K 0.16% 67
2025
Q1
$3.46M Sell
31,036
-910
-3% -$96.9K 0.16% 68
2024
Q4
$3.11M Sell
31,946
-152
-0.5% -$16.2K 0.14% 72
2024
Q3
$3.69M Sell
32,098
-55
-0.2% -$6.24K 0.17% 71
2024
Q2
$3.42M Buy
32,153
+6,223
+24% +$625K 0.16% 70
2024
Q1
$2.51M Sell
25,930
-422
-2% -$43.3K 0.12% 75
2023
Q4
$2.66M Sell
26,352
-675
-2% -$65.2K 0.14% 77
2023
Q3
$2.75M Sell
27,027
-1,547
-5% -$157K 0.16% 76
2023
Q2
$2.88M Buy
28,574
+54
+0.2% +$5.4K 0.16% 73
2023
Q1
$2.62M Sell
28,520
-64
-0.2% -$5.59K 0.16% 75
2022
Q4
$2.59M Sell
28,584
-891
-3% -$75K 0.17% 77
2022
Q3
$2.24M Sell
29,475
-930
-3% -$77.1K 0.15% 77
2022
Q2
$2.57M Sell
30,405
-390
-1% -$34.2K 0.16% 75
2022
Q1
$2.7M Sell
30,795
-311
-1% -$26.9K 0.14% 76
2021
Q4
$2.72M Sell
31,106
-6,906
-18% -$573K 0.13% 76
2021
Q3
$3.11M Sell
38,012
-2,375
-6% -$214K 0.17% 77
2021
Q2
$3.69M Sell
40,387
-1,975
-5% -$176K 0.2% 70
2021
Q1
$3.62M Sell
42,362
-3,142
-7% -$282K 0.21% 67
2020
Q4
$4.3M Sell
45,504
-3,013
-6% -$263K 0.26% 59
2020
Q3
$4.22M Sell
48,517
-28
-0.1% -$2.43K 0.28% 62
2020
Q2
$4.24M Buy
48,545
+2,565
+6% +$221K 0.32% 61
2020
Q1
$3.79M Sell
45,980
-1,180
-3% -$105K 0.35% 62
2019
Q4
$4.47M Sell
47,160
-412
-0.9% -$37K 0.33% 65
2019
Q3
$4.13M Sell
47,572
-109
-0.2% -$9.79K 0.33% 66
2019
Q2
$4.35M Sell
47,681
-5,530
-10% -$468K 0.35% 67
2019
Q1
$4.58M Sell
53,211
-10
-0% -$803 0.39% 59
2018
Q4
$4.09M Sell
53,221
-1,819
-3% -$142K 0.39% 58
2018
Q3
$4.25M Sell
55,040
-11,091
-17% -$820K 0.34% 60
2018
Q2
$4.48M Sell
66,131
-5,175
-7% -$357K 0.38% 61
2018
Q1
$5.17M Buy
71,306
+544
+0.8% +$41.4K 0.46% 62
2017
Q4
$5.32M Sell
70,762
-106
-0.1% -$8K 0.45% 63
2017
Q3
$5.45M Sell
70,868
-391
-0.5% -$29.5K 0.48% 58
2017
Q2
$5.33M Sell
71,259
-3,908
-5% -$277K 0.49% 57
2017
Q1
$5M Sell
75,167
-23,187
-24% -$1.55M 0.47% 60
2016
Q4
$6.42M Sell
98,354
-32,553
-25% -$2.11M 0.62% 54
2016
Q3
$9.26M Sell
130,907
-25,391
-16% -$1.85M 0.93% 43
2016
Q2
$11.6M Sell
156,298
-63,393
-29% -$4.38M 1.16% 36
2016
Q1
$14.3M Sell
219,691
-20,036
-8% -$1.36M 1.47% 31
2015
Q4
$18.5M Buy
239,727
+1,800
+0.8% +$143K 1.92% 17
2015
Q3
$19.6M Sell
237,927
-2,821
-1% -$251K 2.12% 13
2015
Q2
$21.2M Sell
240,748
-2,338
-1% -$214K 2.14% 12
2015
Q1
$21.5M Sell
243,086
-4,586
-2% -$407K 2.11% 13
2014
Q4
$20.6M Buy
247,672
+1,837
+0.7% +$152K 2.01% 15
2014
Q3
$20.7M Buy
245,835
+3,634
+2% +$294K 2.08% 15
2014
Q2
$19.6M Sell
242,201
-511
-0.2% -$40.2K 1.97% 19
2014
Q1
$18.5M Sell
242,712
-2,670
-1% -$195K 1.97% 18
2013
Q4
$17.7M Buy
245,382
+745
+0.3% +$51.8K 1.98% 16
2013
Q3
$16.8M Buy
244,637
+3,720
+2% +$246K 2.04% 16
2013
Q2
$15.3M Buy
+240,917
New +$15.7M 1.96% 17

Other funds holding NVS

Northeast Investment Management's NVS Position: Q2 2026 in Review

Northeast Investment Management reduced its Novartis (NVS) stake by 3.7% in Q2 2026, selling an estimated $161K and leaving 27,819 shares worth $4.36M. The position accounts for 0.16% of the portfolio, ranked #70.

Northeast Investment Management first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $21.5M in Q1 2015. 520 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Northeast Investment Management held 27,819 shares of Novartis worth $4.36M as of Q2 2026.
  • Northeast Investment Management sold 1,073 Novartis shares in Q2 2026, an estimated $161K.
  • Novartis made up 0.16% of Northeast Investment Management's portfolio in Q2 2026, its #70 holding.
  • Northeast Investment Management first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Northeast Investment Management's Novartis position peaked at $21.5M in Q1 2015.
  • 520 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Northeast Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.